重组人LR3 IGF-1（可替代胰岛素，优于胰岛素）
重组人Long R3 IGF-I
Long R3 IGF-I是人IGF-I(胰岛素样生长因子-I)的重组类似物，其在IGF-I全长氨基酸序列的第3位将谷氨酸变为精氨酸，并在N端添加一条长为13个氨基酸的肽。因此可见，Long代表N端加长，而R3代表第3位被精氨酸(R)所取代。
Long R3 IGF-I是人IGF-I(胰岛素样生长因子-I)的重组类似物，其在IGF-I全长氨基酸序列的第3位将谷氨酸变为精氨酸，并在N端添加一条长为13个氨基酸的肽。因此可见，Long代表N端加长，而R3代表第3位被精氨酸(R)所取代。
优于Insulin
Insulin(胰岛素)是无血清细胞培养基的常见添加物，用以促进细胞生长。然而，细胞表面的胰岛素受体(IR)通常远少于IGF-I受体(IGF-IR)。Long R3 IGF-I因能与IGF-IR高度特异性结合，所以其促进细胞增殖、细胞存活和细胞蛋白产生的能力可强于Insulin 200倍之多。
优于天然的IGF-I
所有哺乳动物均分泌IGF结合蛋白(IGFBPs)，该蛋白可与天然的IGF-I结合并一直后者的活性。Long R3 IGF-I是经过改造的IGF-I，其与IGFBPs的亲合力较天然蛋白降低1000倍以上，因此Long R3 IGF-I的生物活性和效能比天然的IGF-I大为提高。
重组Long R3 IGF-I主要可以替代Insulin和IGF-I，用于无血清或低血清细胞培养。可以：
1. 针对性改造使其促生长活性远高于胰岛素；
2. 体内半衰期延长，活性优于天然的IGF-I；
3. 可提高细胞表达重组蛋白的产量；
4. 科研级别和工业规模细胞培养均适合；
5. 适用于培养HEK293，CHO，BHK，MDCK，PER.C6，Vero和成纤维细胞等多种细胞；
6. 价格低于IGF-I。
Recombinant Human IGF-I LR3
Synonyms:
Long R3 IGF-I, Insulin-like Growth Factor-I, Somatamedin C, IGF-IA
Description:
The IGFs are mitogenic, polypeptide growth factors that stimulate the proliferation and survival of various cell types, including muscle, bone, and cartilage tissue in vitro. IGFs are predominantly produced by the liver, although a variety of tissues produce the IGFs at distinctive times. The IGFs belong to the Insulin gene family, which also contains insulin and relaxin. The IGFs are similar to insulin by structure and function, but have a much higher growth-promoting activity than insulin. IGF-II expression is influenced by placenta lactogen, while IGF-I expression is regulated by growth hormone. Both IGF-I and IGF-II signal through the tyrosine kinase type I receptor (IGF-IR), but IGF-II can also signal through the IGF-II/Mannose-6-phosphate receptor. Mature IGFs are generated by proteolytic processing of inactive precursor proteins, which contain N-terminal and C-terminal propeptide regions. Recombinant human IGF-I and IGF-II are globular proteins containing 70 and 67 amino acids, respectively, and 3 intra-molecular disulfide bonds. IGF-I LR3 is a recombinant analog of human IGF-I comprised of the complete IGF-I sequence, with an Arginine substitution for the third position Glutamic acid, and a 13 amino acid length N terminus peptide extension. Specifically engineered for higher biological potency in vitro, IGF-I LR3 has an increased half-life and a binding aversion to native proteins within the body that make it ideal for both research and large-scale culturing. Recombinant Human IGF-I LR3 is a 9.1 kDa, single, non-glycosylated polypeptide chain containing 83 amino acid residues.
AA Sequence:
MFPAMPLSSL FVNGPRTLCG AELVDALQFV CGDRGFYFNK PTGYGSSSRR APQTGIVDEC CFRSCDLRRL EMYCAPLKPA KSA
Source:
E.coli
Purity:
Greater than 98% by SDS-PAGE gel and HPLC analyses.
Biological Activity:
The ED50 was determined by a cell proliferation assay using FDC-P1 cells is ≤ 2.0 ng/ml, corresponding to a specific activity of ≥ 5 x 105 units/mg.
技术资料